© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 6, 488-489,
March 19, 2003
© 2003 Oxford University Press
CORRESPONDENCE |
Acute Bilateral Abducens Paralysis Due to Oxaliplatin
Affiliations of authors: E. Winquist, M. Vincent, Division of Medical Oncology, London Regional Cancer Centre and University of Western Ontario, London, Ontario, Canada; W. Stadler, Department of Medicine, University of Chicago, Chicago. IL.
Correspondence to: Eric Winquist, M.D., London Regional Cancer Centre, 790 Commissioners Rd. East, London, Ontario, Canada N6A 4L6 (e-mail: eric.winquist@lrcc.on.ca).
| The first 10% of the full text of this article appears below. |
Oxaliplatin (trans-l-1,2-diaminocyclohexane oxalatoplatinum) inhibits DNA synthesis by cross-linking DNA (1). Oxaliplatin also interferes with the DNA mismatch repair enzyme complex by decreasing replicative bypass of platinum-DNA adducts, making it of possible therapeutic interest for cisplatin-resistant tumors. Oxaliplatins principal dose-limiting toxicity is sensory neuropathy, with both acute and chronic components. Acute neurotoxicity is often cold-induced